These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

71 related articles for article (PubMed ID: 18566037)

  • 1. Breastfeeding and multiple sclerosis in a German cohort.
    Hellwig K; Gold R
    Mult Scler; 2008 Jun; 14(5):718. PubMed ID: 18566037
    [No Abstract]   [Full Text] [Related]  

  • 2. Intravenous immunoglobulin in relapsing-remitting multiple sclerosis: a dose-finding trial.
    Engel WK
    Neurology; 2009 Sep; 73(13):1077; author reply 1077-8. PubMed ID: 19786702
    [No Abstract]   [Full Text] [Related]  

  • 3. Intravenous immunoglobulin in relapsing-remitting multiple sclerosis: a dose-finding trial.
    Khan OA; Tselis A; Boster A
    Neurology; 2009 Jun; 72(24):2134; author reply 2134-5. PubMed ID: 19528523
    [No Abstract]   [Full Text] [Related]  

  • 4. Intravenous immunoglobulin in relapsing-remitting multiple sclerosis: a dose-finding trial.
    Fazekas F; Lublin FD; Li D; Freedman MS; Hartung HP; Rieckmann P; Sørensen PS; Maas-Enriquez M; Sommerauer B; Hanna K; ;
    Neurology; 2008 Jul; 71(4):265-71. PubMed ID: 18645164
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intravenous immunoglobulins, pregnancy and multiple sclerosis.
    Confavreux C
    J Neurol; 2004 Sep; 251(9):1138-9. PubMed ID: 15372260
    [No Abstract]   [Full Text] [Related]  

  • 6. Relapse management in multiple sclerosis.
    Thrower BW
    Neurologist; 2009 Jan; 15(1):1-5. PubMed ID: 19131851
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Benefits of glatiramer acetate in the treatment of relapsing-remitting multiple sclerosis.
    Johnson KP; Due DL
    Expert Rev Pharmacoecon Outcomes Res; 2009 Jun; 9(3):205-14. PubMed ID: 19527092
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Multiple sclerosis and reproductive risks in women.
    Argyriou AA; Makris N
    Reprod Sci; 2008 Oct; 15(8):755-64. PubMed ID: 19017813
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Switching to second-line therapies in interferon-beta-treated relapsing-remitting multiple sclerosis patients.
    Portaccio E; Zipoli V; Siracusa G; Sorbi S; Amato MP
    Eur Neurol; 2009; 61(3):177-82. PubMed ID: 19129705
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Natalizumab for multiple sclerosis?
    Drug Ther Bull; 2008 Sep; 46(9):69-72. PubMed ID: 18784381
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HLA class I and II alleles and response to treatment with interferon-beta in relapsing-remitting multiple sclerosis.
    Comabella M; Fernández-Arquero M; Río J; Guinea A; Fernández M; Cenit MC; de la Concha EG; Montalban X
    J Neuroimmunol; 2009 May; 210(1-2):116-9. PubMed ID: 19349081
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Therapeutic strategies for multiple sclerosis--update 2008].
    Kanter vI; Mäurer M
    MMW Fortschr Med; 2008 Jun; 150(23):42-5. PubMed ID: 18575371
    [No Abstract]   [Full Text] [Related]  

  • 13. Magnetic resonance imaging as a surrogate for treatment effect on multiple sclerosis relapses.
    Arnold DL; Goodin DS
    Ann Neurol; 2009 Mar; 65(3):237-8. PubMed ID: 19334057
    [No Abstract]   [Full Text] [Related]  

  • 14. Interferon-beta1b in multiple sclerosis: effect on progression of disability and clinical markers of treatment response.
    Carmona O; Casado V; Moral E; Alonso-Magdalena L; Martínez-Yélamos A; Martínez-Yélamos S; Martín-Ozaeta G; Arbizu T
    Eur Neurol; 2008; 60(6):279-84. PubMed ID: 18824855
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interferon beta-1a induces tumor necrosis factor receptor 1 but decreases tumor necrosis factor receptor 2 leukocyte mRNA levels in relapsing-remitting multiple sclerosis.
    Reuss R; Pohle S; Retzlaff K; Hemberger J; Oschmann P
    Neuroimmunomodulation; 2009; 16(3):171-6. PubMed ID: 19246939
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cognitive impairment and its relation with disease measures in mildly disabled patients with relapsing-remitting multiple sclerosis: baseline results from the Cognitive Impairment in Multiple Sclerosis (COGIMUS) study.
    Patti F; Amato MP; Trojano M; Bastianello S; Tola MR; Goretti B; Caniatti L; Di Monte E; Ferrazza P; Brescia Morra V; Lo Fermo S; Picconi O; Luccichenti G;
    Mult Scler; 2009 Jul; 15(7):779-88. PubMed ID: 19542262
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interferon beta therapy increases serum ferritin levels in patients with relapsing-remitting multiple sclerosis.
    Sena A; Pedrosa R; Ferret-Sena V; Cascais MJ; Roque R; Araújo C; Couderc R
    Mult Scler; 2008 Jul; 14(6):857-9. PubMed ID: 18573825
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A pilot test of pioglitazone as an add-on in patients with relapsing remitting multiple sclerosis.
    Kaiser CC; Shukla DK; Stebbins GT; Skias DD; Jeffery DR; Stefoski D; Katsamakis G; Feinstein DL
    J Neuroimmunol; 2009 Jun; 211(1-2):124-30. PubMed ID: 19446890
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Promising outcomes from Phase III CLARITY study for the treatment of multiple sclerosis announced.
    Expert Rev Pharmacoecon Outcomes Res; 2009 Jun; 9(3):198. PubMed ID: 19527090
    [No Abstract]   [Full Text] [Related]  

  • 20. Home administration of intravenous methylprednisolone for multiple sclerosis relapses: the experience of French multiple sclerosis networks.
    Créange A; Debouverie M; Jaillon-Rivière V; Taithe F; Liban D; Moutereau A; Clavelou P; Defer G
    Mult Scler; 2009 Sep; 15(9):1085-91. PubMed ID: 19556312
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.